CATX Perspective Therapeutics, Inc.
Pharmaceutical Preparations · NYSE · SEC CIK 728387 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-16.2%
TTM EPS YoY16.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-45.8%
ROA-37.2%
ROIC (approx.)-44.1%
Asset turnover—
Leverage & solvency
Liabilities / assets19.4%
Debt / equity0.01x
Current ratio5.18x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.88x
Accruals ratio-4.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $84.22M | $41.64M |
| SG&A expense | $30.23M | $26.61M |
| Operating income | -$113.56M | -$90.89M |
| Pretax income | -$104.43M | -$80.43M |
| Income tax | -$793,000 | -$2.10M |
| Net income | -$103.12M | -$79.28M |
| EBITDA | -$110.31M | -$88.58M |
| EPS (basic) | -1.40 | -1.23 |
| EPS (diluted) | -1.40 | -1.23 |
| Weighted avg. shares (diluted) | 73.81M | 64.42M |
| Balance sheet | ||
| Cash & equivalents | $30.63M | $61.58M |
| Short-term investments | $114.11M | $165.34M |
| Receivables | $6,000 | $116,000 |
| Current assets | $148.39M | $231.16M |
| PP&E, net | $76.60M | $57.32M |
| Goodwill | — | $0 |
| Intangibles | $362,000 | $279,000 |
| Total assets | $266.97M | $341.10M |
| Current liabilities | $28.68M | $18.23M |
| Long-term debt | $1.62M | $1.68M |
| Total debt | $1.62M | $1.68M |
| Total liabilities | $59.94M | $50.43M |
| Shareholders' equity | $207.03M | $290.67M |
| Net debt | -$29.00M | -$59.90M |
| Shares outstanding | 74.34M | 70.67M |
| Cash flow statement | ||
| Operating cash flow | -$82.48M | -$18.29M |
| Capital expenditure | $12.75M | $54.41M |
| Free cash flow | -$95.23M | -$72.71M |
| Investing cash flow | $41.23M | -$218.93M |
| Financing cash flow | $10.30M | $289.38M |
| Depreciation & amortization | $3.25M | $2.31M |
| Stock-based compensation | $8.97M | $5.39M |
Free plan shows the latest 2 periods; Pro shows all 16 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.